Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants

Firdausi Qadri, Mohiul I. Chowdhury, Shah M. Faruque, Mohammed A. Salam, Tanvir Ahmed, Yasmin A. Begum, Amit Saha, Abdullah Al Tarique, Lorenz V. Seidlein, Eunsik Park, Kevin P. Killeen, John J. Mekalanos, John D. Clemens, David A. Sack

Research output: Contribution to journalArticlepeer-review

78 Scopus citations

Abstract

A live oral Vibrio cholerae O1 El Tor vaccine, Peru-15 was tested in a double-blind, randomized placebo controlled study for safety and immunogenicity in Phase I and Phase II studies in 240 Bangladeshi children aged 9 months-5 years of age. Two different doses (2 × 107 and 2 × 108 cfu) were tested. Vaccination did not elicit adverse events and the strain was genetically stable. Vibriocidal antibody responses developed in 42/50 (84%) toddlers (2-5 years) and 35/50 (70%) of younger children (9-23 months) and overall 77/100 (77%) who received the high dose. LPS-IgA-antibody responses were seen in 60% of toddlers and 34% of infants; 40% responded with IgA antibodies to cholera toxin. The responses to the reduced dose was lower. These studies demonstrate that Peru-15 at a dose of 2 × 108 cfu is safe and immunogenic in children in Bangladesh.

Original languageEnglish (US)
Pages (from-to)231-238
Number of pages8
JournalVaccine
Volume25
Issue number2
DOIs
StatePublished - Jan 4 2007
Externally publishedYes

Keywords

  • Bangladeshi children
  • Immunogenicity
  • Peru-15

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants'. Together they form a unique fingerprint.

Cite this